## In the Claims

Please replace all prior versions, and listings, of claims in the application with the following list of claims:

- 1-57. (Canceled)
- 58. (Currently Amended) A method for delivering a glycosaminoglycan to a subject, comprising, administering to a pulmonary tissue of a subject an unformulated dry glycosaminoglycan having a mean diameter of 1-500 micronsthe glycosaminoglycan of claim 43.
  - 59-115. (Canceled)
- 116. (Currently Amended) The <u>method of claim 58unformulated dry glycosaminoglycan</u> of claim 43, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-200 microns.
- 117. (Currently Amended) The <u>method of claim 58unformulated dry glycosaminoglycan</u> of claim 43, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-53 microns.
- 118. (Currently Amended) The <u>method of claim 58unformulated dry glycosaminoglycan</u> of claim 43, wherein the unformulated <u>dry</u> glycosaminoglycan has a mean geometric diameter of 1-5 microns.
- 119. (Currently Amended) The <u>method of claim 58unformulated dry glycosaminoglycan</u> of claim 43, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 5-53 microns.

Docket No.: M0656.70070US00

Application No. 09/982,548

Confirmation No.: 7782

(Currently Amended) The method of claim 58unformulated dry glycosaminoglycan 120. of claim 43, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 53-106 microns.

3

(Currently Amended) The method of claim 58unformulated dry glycosaminoglycan of claim 43, wherein the glycosaminoglycan is a heparin, a heparan sulfate, a low molecular weight heparin.

122-203. (Canceled)

(Currently Amended) The method of claim 58unformulated dry glycosaminoglycan 204. of claim 43, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 10-500 microns.

(Canceled) 205.

- (Currently Amended) The method of claim 58unformulated dry glycosaminoglycan 206. of claim 43, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 10-250 microns.
- (Currently Amended) The method of claim 58unformulated dry glycosaminoglycan of claim 43, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 10-100 microns.
- 208. (Currently Amended) The method of claim 58unformulated dry glycosaminoglycan of claim 43, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 100-200 microns.

Docket No.: M0656.70070US00

Application No. 09/982,548

Confirmation No.: 7782

209. (Currently Amended) The method of claim 58unformulated dry glycosaminoglycan of claim 43, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 100-150 microns.

4

## 210. (Canceled)

- 211. (Currently Amended) The <u>method of claim 58unformulated dry glycosaminoglycan</u> of claim 43, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 20-53 microns.
- 212. (Currently Amended) The <u>method of claim 58unformulated dry glycosaminoglycan</u> of claim 43, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 53-75 microns.
- 213. (Currently Amended) The <u>method of claim 58unformulated dry glycosaminoglycan</u> of claim 43, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 75-106 microns.

## 214-222. (Canceled)

- 223. (Currently Amended) The <u>method of claim 58unformulated dry glycosaminoglycan</u> of claim 43, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-50 microns.
- 224. (Currently Amended) The method of claim 58unformulated dry glycosaminoglycan of claim 43, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-20 microns.

Application No. 09/982,548 5 Docket No.: M0656.70070US00

Confirmation No.: 7782

225. (Currently Amended) The <u>method of claim 58unformulated dry glycosaminoglycan</u> of claim 43, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-100 microns.

- 226. (Currently Amended) The <u>method of claim 58unformulated dry glycosaminoglycan</u> of claim 43, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-250 microns.
- 227. (Currently Amended) The <u>method of claim 58unformulated dry glycosaminoglycan</u> of claim 43, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 5-200 microns.
- 228. (Currently Amended) The <u>method of claim 58unformulated dry glycosaminoglycan</u> of claim 43, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 5-30 microns.
- 229. (Currently Amended) The method of claim 58unformulated dry glycosaminoglycan of claim 43, wherein the unformulated dry glycosaminoglycan has a tap density of 0.01 0.4 g/cm<sup>3</sup>.
- 230. (Currently Amended) The method of claim 58unformulated dry glycosaminoglycan of claim 43, wherein the unformulated dry glycosaminoglycan has a tap density of greater than 0.4 g/cm<sup>3</sup>.
- 231. (Currently Amended) The method of claim 58unformulated dry glycosaminoglycan of claim 43, wherein the unformulated dry glycosaminoglycan has a tap density of less than 0.4 g/cm<sup>3</sup>.
- 232. (Currently Amended) A method for producing a therapeutic effect, comprising, administering to a pulmonary tissue of a subject an unformulated dry glycosaminoglycan having a mean diameter of 1-500 micronsthe glycosaminoglycan of claim 43.

Application No. 09/982,548 Confirmation No.: 7782

## 233-237. (Canceled)

- 238. (Previously Presented) The method of claim 232, wherein the therapeutic effect is treatment of a coagulation disorder, a thrombotic disorder, a cardiovascular disease, a vascular condition, atherosclerosis, a respiratory disorder, cancer, an angiogenic disorder, circulatory shock or Alzheimer's disease.
- 239. (New) An unformulated dry glycosaminoglycan having a mean geometric diameter of 1-53 microns.
- 240. (New) An unformulated dry glycosaminoglycan having a mean geometric diameter of 1-5 microns.
- 241. (New) An unformulated dry glycosaminoglycan having a mean geometric diameter of 5-53 microns.
- 242. (New) An unformulated dry glycosaminoglycan having a mean geometric diameter of 53-106 microns.
- 243. (New) An unformulated dry glycosaminoglycan having a mean geometric diameter of 10-500 microns.
- 244. (New) An unformulated dry glycosaminoglycan having a mean geometric diameter of 10-100 microns.
- 245. (New) An unformulated dry glycosaminoglycan having a mean geometric diameter of 100-150 microns.

Docket No.: M0656.70070US00

Application No. 09/982,548 Confirmation No.: 7782

7

- 246. (New) An unformulated dry glycosaminoglycan having a mean geometric diameter of 20-53 microns.
- 247. (New) An unformulated dry glycosaminoglycan having a mean geometric diameter of 53-75 microns.
- 248. (New) An unformulated dry glycosaminoglycan having a mean geometric diameter of 75-106 microns.
- 249. (New) An unformulated dry glycosaminoglycan having a mean geometric diameter of 1-50 microns.
- 250. (New) An unformulated dry glycosaminoglycan having a mean geometric diameter of 1-20 microns.
- 251. (New) An unformulated dry glycosaminoglycan having a mean geometric diameter of 1-100 microns.
- 252. (New) An unformulated dry glycosaminoglycan having a mean geometric diameter of 5-30 microns.